UBI集團訊息
TAG :UBI group
-
-
View More 
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infectionUBI集團訊息United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
They have received Investigational New Drug (IND) approval from Taiwan FDA to conduct a Phase 3 clinical trial with UB-421 in patients with multi-drug resistant (MDR) HIV-1 infection. -
View More 
聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲台灣FDA核准執行UBI集團訊息聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲台灣FDA核准執行
UB-421應用於治療多重抗藥性(multi-drug resistant (MDR)HIV感染病患之3期臨床試驗已獲台灣FDA核准執行 -
View More 
Why coronavirus antibody testing in one Colorado town could provide a way forwardUBI集團訊息Why coronavirus antibody testing in one Colorado town could provide a way forward
Testing in the ski town Telluride could allow for fewer restrictions nationwide. -
View More 
「我們的任務是在這個非我所願的複雜混沌的時刻，展示自己最好的品格和行為。願我們與智慧和風度同行。」– Lawrence Bacow, President of Harvard UniversityUBI集團訊息「我們的任務是在這個非我所願的複雜混沌的時刻，展示自己最好的品格和行為。願我們與智慧和風度同行。」– Lawrence Bacow, President of Harvard University
UNITED BIOMEDICAL GROUP’S C19 COMPANY PARTNERS WITH SAN MIGUEL COUNTY, COLORADO TO BE FIRST IN NATION TO TEST AN ENTIRE COUNTY FOR COVID-19 WITH NEW ANTIBODY DIAGNOSTIC TEST -
View More 
Frequently asked questions about UBI SARS-CoV2 ELISAUBI集團訊息Frequently asked questions about UBI SARS-CoV2 ELISA
Frequently asked questions about UBI SARS-CoV2 ELISA -
View More 
Why a Tiny Colorado County Can Offer COVID-19 Tests to Every ResidentUBI集團訊息Why a Tiny Colorado County Can Offer COVID-19 Tests to Every Resident
There are advantages to having biotech executives as neighbors. -
View More 為什麼一個科羅拉多州的小縣可以讓所有居民做新冠肺炎篩檢？
-
View More 
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy VolunteersUBI集團訊息United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers
An Investigational New Drug (IND) application from China National Medical Products Administration (NMPA) to conduct a phase 1 clinical trial with the company’s anti-IgE UB-221 -
View More 
聯生藥抗體新藥UB-221獲中國NMPA核准進行臨床I期試驗UBI集團訊息聯生藥抗體新藥UB-221獲中國NMPA核准進行臨床I期試驗
中國國家藥品監督管理局(National Medical Products Administration，NMPA)已核准其開發中抗體新藥UB-221之I 期臨床試驗的申請 -
View More 
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV PatientsUBI集團訊息United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
They have received Investigational New Drug (IND) approval from China National Medical Products Administration (NMPA) to conduct a Phase 2 clinical trial to evaluate UB-421’s efficacy -
View More 
中國NMPA核准聯生藥治療愛滋病抗體新藥UB-421 之一項評估減少病患HIV病毒儲存庫的臨床II期試驗申請UBI集團訊息中國NMPA核准聯生藥治療愛滋病抗體新藥UB-421 之一項評估減少病患HIV病毒儲存庫的臨床II期試驗申請
中國國家藥品監督管理局(NMPA)核准其治療HIV-1感染抗體新藥UB-421之II 期功能性治癒概念驗證臨床試驗的申請
-
-
View More 
我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！ -
View More 
我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力–我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力– -
View More 
我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏
